Development and validation of the compulsive-buying follow-up scale: A measure to assess treatment improvements in compulsive buying disorder

Imagem de Miniatura
Arquivos
art_MATTOS_Development_and_validation_of_the_compulsivebuying_followup_scale_2019.PDF (532.07 KB)
Citações na Scopus
7
Tipo de produção
article
Data de publicação
2019
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER IRELAND LTD
Autores
KIM, Hyoun S.
Citação
PSYCHIATRY RESEARCH, v.282, article ID 112009, 7p, 2019
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
The aim of the present research was to develop a scale to assess treatment improvements for compulsive buying disorder (CBD), adapted from the Gambling Follow-up Scale Self-Report Version. The Compulsive Buying Follow-up Scale (CBFS) contains six self-report multiple-choice items assessing different aspects of compulsive buying in the past four weeks. Forty-eight treatment-seeking patients with CBD were evaluated, with 39 patients completing the 12-week follow-up. The scale's global alpha was high as well as the item-total correlations per item. The estimations of alpha if-item-deleted were all under the global alpha value, indicating that all items provided relevant contribution within the scale. The CBFS demonstrated significant correlations with previously developed scales of CBD and other measures of psychopathology, with the exception of a non-significant association with the Beck Depression Inventory at pre-treatment. The CBFS correlated significantly with all reference scales at post-treatment. The CBFS also demonstrated strong sensitivity to change and recovery status. The cutoff for the CBFS that provided the greatest sensitivity (0.93) and specificity (0.82) was 22. The results provide support that CBFS is a reliable and valid instrument to measure treatment outcomes over time for CBD.
Palavras-chave
Compulsive buying disorder, Follow-up scale, Treatment outcomes
URI
https://observatorio.fm.usp.br/handle/OPI/34530
Referências
  1. BECK AT, 1988, CLIN PSYCHOL REV, V8, P77, DOI 10.1016/0272-7358(88)90050-5
  2. Black DW, 2016, COMPR PSYCHIAT, V68, P97, DOI 10.1016/j.comppsych.2016.03.004
  3. Black Donald W, 2010, Dialogues Clin Neurosci, V12, P175
  4. Black DW, 2001, CNS DRUGS, V15, P17, DOI 10.2165/00023210-200115010-00003
  5. Black DW, 1996, J CLIN PSYCHIAT, V57, P50
  6. Bohne A, 2010, PSYCHIAT RES, V176, P91, DOI 10.1016/j.psychres.2009.03.025
  7. CHRISTENSON GA, 1994, J CLIN PSYCHIAT, V55, P5
  8. Claes L, 2012, EUR EAT DISORD REV, V20, P126, DOI 10.1002/erv.1136
  9. COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155
  10. Cohen J., 1988, STAT POWER ANAL BEHA
  11. Cole L, 1995, ADV CONSUM RES, V22, P419
  12. Core Team R, 2015, R LANG ENV STAT COMP
  13. DAHLKE F, 1992, PSYCHOPHARMACOL BULL, V28, P425
  14. Di Nicola M, 2015, DRUG ALCOHOL DEPEN, V148, P118, DOI 10.1016/j.drugalcdep.2014.12.028
  15. Edwards Elizabeth A., 1993, FINANCIAL COUNSELING, V4, P67
  16. FABER RJ, 1989, ADV CONSUM RES, V16, P738
  17. FABER RJ, 1992, J CONSUM RES, V19, P459, DOI 10.1086/209315
  18. First M.B., 1997, US GUID
  19. Galetti AM, 2017, REV BRAS PSIQUIATR, V39, P36, DOI 10.1590/1516-4446-2016-1911
  20. GOODMAN WK, 1989, ARCH GEN PSYCHIAT, V46, P1012
  21. Gorenstein C, 2002, J AFFECT DISORDERS, V69, P167, DOI 10.1016/S0165-0327(01)00300-7
  22. Gorenstein C., 1998, REV PSIQUIATRIA CLIN, V25, P245
  23. Granero R, 2017, EUR PSYCHIAT, V39, P57, DOI 10.1016/j.eurpsy.2016.06.004
  24. Granero R, 2016, FRONT PSYCHOL, V7, DOI 10.3389/fpsyg.2016.00914
  25. Granero R, 2016, FRONT PSYCHOL, V7, DOI 10.3389/fpsyg.2016.00625
  26. Guy W., 1976, ASSESSMENT MANUAL PS, p[76, 218]
  27. Hague B, 2016, J BEHAV ADDICT, V5, P379, DOI 10.1556/2006.5.2016.064
  28. Hodgins DC, 2008, REV BRAS PSIQUIATR, V30, pS31, DOI 10.1590/S1516-44462006005000055
  29. Hollander E, 1996, J CLIN PSYCHIAT, V57, P3
  30. Kellett S, 2009, CLIN PSYCHOL PSYCHOT, V16, P83, DOI 10.1002/cpp.585
  31. Koran LM, 2006, AM J PSYCHIAT, V163, P1806, DOI 10.1176/appi.ajp.163.10.1806
  32. Kuss DJ, 2016, WORLD J PSYCHIATR, V6, P143, DOI 10.5498/wjp.v6.i1.143
  33. Leite P, 2013, REV BRAS PSIQUIATR, V35, P38, DOI 10.1016/j.rbp.2012.10.004
  34. Leite PL, 2014, PSYCHIAT RES, V219, P411, DOI 10.1016/j.psychres.2014.05.037
  35. Leite PL, 2014, COMPR PSYCHIAT, V55, P1462, DOI 10.1016/j.comppsych.2014.04.012
  36. Leite Priscilla Lourenço, 2011, J. bras. psiquiatr., V60, P176, DOI 10.1590/S0047-20852011000300005
  37. Lejoyeux M, 1996, AM J PSYCHIAT, V153, P1524
  38. Lejoyeux M, 2010, AM J DRUG ALCOHOL AB, V36, P248, DOI 10.3109/00952990.2010.493590
  39. Maraz A, 2016, ADDICTION, V111, P408, DOI 10.1111/add.13223
  40. MCELROY SL, 1994, J CLIN PSYCHIAT, V55, P242
  41. MCELROY SL, 1995, J CLIN PSYCHIAT, V56, P14
  42. MCELROY SL, 1995, J CLIN PSYCHIAT S4, V56, P7
  43. Medeiros G.C., 2017, PSYCHIAT RES, V8
  44. Miltenberger RG, 2003, J BEHAV THER EXP PSY, V34, P1, DOI 10.1016/S0005-7916(03)00002-8
  45. Monahan P, 1996, PSYCHIAT RES, V64, P59, DOI 10.1016/0165-1781(96)02908-3
  46. Phau I, 2008, MARK INTELL PLAN, V26, P587, DOI 10.1108/02634500810902848
  47. Quinn S., 2008, EC REV
  48. Rehm J, 2017, ADDICTION, V112, P968, DOI 10.1111/add.13757
  49. Ridgway N.M., 2008, J CONSUM RES, V35, P350
  50. Robin X, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-77
  51. Rockloff MJ, 2012, J GAMBL STUD, V28, P207, DOI 10.1007/s10899-011-9260-2
  52. Soares C, 2016, CNS DRUGS, V30, P281, DOI 10.1007/s40263-016-0324-9
  53. Suss HM, 2000, Z EXP PSYCHOL, V47, P162
  54. Tavares H, 2008, REV BRAS PSIQUIATR, V30, pS16, DOI 10.1590/S1516-44462008005000002
  55. VALENCE G, 1988, J CONSUM POLICY, V11, P419, DOI 10.1007/BF00411854
  56. Weinstein Aviv, 2016, NEUROPATHOLOGY DRUG, P993, DOI 10.1016/B978-0-12-800634-4.00098-6
  57. WEISSMAN MM, 1976, ARCH GEN PSYCHIAT, V33, P1111
  58. Zhou X.H., 2002, K STAT METHODS DIAGN

Coleções
Artigos e Materiais de Revistas Científicas - FM/MPS
Artigos e Materiais de Revistas Científicas - HC/IPq
Artigos e Materiais de Revistas Científicas - LIM/23